Nedosiran is a GalNAc-conjugated double-stranded RNAi therapeutic targeting lactate dehydrogenase (LDH) for primary hyperoxaluria. It is investigated in preclinical and clinical studies for reducing oxalate production, offering a potential treatment for patients with PH and ESRD.
CAS Number:
[2266591-83-5]
Target:
Dehydrogenase
* VAT and and shipping costs not included. Errors and price changes excepted